Connor, Clark & Lunn Investment Management Ltd. Tcr2 Therapeutics Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$1.86 - $3.75 $26,713 - $53,857
14,362 New
14,362 $26,000
Q1 2022

May 12, 2022
SELL
$2.4 - $4.71 $69,024 - $135,459
-28,760 Closed
0 $0
Q4 2021

Feb 10, 2022
BUY
$4.58 - $8.34 $20,348 - $37,054
4,443 Added 18.27%
28,760 $134,000
Q3 2021

Nov 12, 2021
BUY
$8.44 - $18.35 $205,235 - $446,216
24,317 New
24,317 $207,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email